ArticleCell insight2026
Molecular basis of fox ACE2 recognition by receptor binding domains of SARS-CoV-2 and PCoV-GD.
Article in Cell insight, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) positive RNA detected in red fox swab samples provide evidence of a natural SARS-CoV-2 infection in this species. Many studies have also demonstrated that the red fox angiotensin converting enzyme 2 (fACE2) could serve as the receptor of SARS-CoV-2 and many SARS-CoV-2 related sarbecoviruses. However, the molecular mechanisms of fACE2 attached by animal-origin coronaviruses remain poorly understood. Here, we found that fACE2 could mediate pseudovirus entry and cell membrane fusion induced by the SARS-CoV-2 and pangolin coronavirus isolated from Guangdong (PCoV-GD) spikes as human ACE2 (hACE2). The binding affinity of fACE2 bound to the receptor-binding domain (RBD) of PCoV-GD was stronger than the SARS-CoV-2 RBD demonstrated by surface plasmon resonance (SPR) assay, while deglycosylation of PCoV-GD RBD N370 by T372A mutation or glycosylation of SARS-CoV-2 RBD N370 by A372T mutation had little effect on fACE2 binding compared with wild-type (WT) RBD. We further solved the crystal structures of fACE2 bound to SARS-CoV-2 RBD and PCoV-GD T372A mutant RBD. Interface analysis and SPR assay revealed that the R417 and H498 of PCoV-GD RBD might account for the binding affinity enhancement with fACE2 compared with K417 and Q498 of SARS-CoV-2 RBD. Moreover, the Y453F mutation in SARS-CoV-2 RBD increased the binding affinity to fACE2 while this mutation in PCoV-GD RBD decreased the binding affinity to fACE2 compared with the corresponding WT RBDs. Furthermore, the RBDs of many prevalent SARS-CoV-2 variants could all bind to fACE2. Our results indicated that the continuous surveillance of SARS-CoV-2 and related sarbecoviruses in fox species was also necessary to better prevent animal-to-human spillover of the coronaviruses.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.